Breaking News, Collaborations & Alliances

PhoreMost Achieves Second Boehringer Milestone in Target Discovery Alliance

PhoreMost deploys next-gen phenotypic screening platform, SITESEEKER, towards novel disease-relevant pathways focusing on retinal health.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PhoreMost Ltd. has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. PhoreMost has identified and validated novel targets supporting Boehringer’s aim to develop first-in-class therapies.   The companies entered a multi-project collaboration back in January 2020. In this second project, PhoreMost is deploying its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, towards novel disease-relevant pathw...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters